TY - JOUR
T1 - Hypoglycemia after gastric bypass surgery
T2 - Current concepts and controversies
AU - Salehi, Marzieh
AU - Vella, Adrian
AU - McLaughlin, Tracey
AU - Patti, Mary Elizabeth
N1 - Funding Information:
Financial Support: This work was supported by the National Institutes of Health Grants DK083554-05 (to M.S.), DK105379 (to M.S.), DK78646 (to A.V.), DK116231 (to A.V.), U01 DK114156 (to M.-E.P.), and R44 DK107114 (to M.-E.P.); Cincinnati Children’s Hospital Clinical Research Center (UL1 TR000077);MayoClinicGeneralClinicalResearchCenter(UL1 TR000135); and P30 DK 036836 (DRC Joslin Diabetes Center).
Funding Information:
This work was supported by the National Institutes of Health Grants DK083554-05 (to M.S.), DK105379 (to M.S.), DK78646 (to A.V.), DK116231 (to A.V.), U01 DK114156 (to M.-E.P.), and R44 DK107114 (to M.-E.P.); Cincinnati Children's Hospital Clinical Research Center (UL1 TR000077); Mayo Clinic General Clinical Research Center (UL1 TR000135); and P30DK036836 (DRC Joslin Diabetes Center).
Funding Information:
Disclosure Summary: M.S. has consulted for Eiger Pharmaceuticals. A.V. is an investigator in an investigator-initiated study, sponsored by Novo Nordisk, and has consulted for vTv Therapeutics, XOMA, Sanofi-Aventis, and Novartis in the past 5 years. T.M. has received research support from Novartis and Novo Nordisk and has consulted for Eiger Pharmaceuticals. M.-E.P. is a coinvestigator on a National Institutes of Health R44 grant together with Xeris Pharmaceuticals; has consulted for Eiger Pharmaceuticals; has received investigator-initiated grant support from Janssen Pharmaceuticals, Medimmune, Sanofi, Astra-Zeneca, Jenesis, and Nuclea; has been a site investigator for XOMA; acknowledges clinical trial research trial product support from Ethicon, Covidien, NovoNordisk, Nestle, and Dexcom within the past 5 years; and has submitted a patent application regarding plasma proteins contributing to hypoglycemia.
Publisher Copyright:
Copyright © 2018 Endocrine Society.
PY - 2018
Y1 - 2018
N2 - Context: Hypoglycemia, occurring after bariatric and other forms of upper gastrointestinal surgery, is increasingly encountered by clinical endocrinologists. The true frequency of this condition remains uncertain, due, in part, to differences in the diagnostic criteria and in the affected populations, as well as relative lack of patient and physician awareness and understanding of this condition. Postbariatric hypoglycemia can be severe and disabling for some patients, with neuroglycopenia (altered cognition, seizures, and loss of consciousness) leading to falls, motor vehicle accidents, and job and income loss. Moreover, repeated episodes of hypoglycemia can result in hypoglycemia unawareness, further impairing safety and requiring the assistance of others to treat hypoglycemia. Objective: In this review, we summarize and integrate data from studies of patients affected by hypoglycemia after Roux-en-Y gastric bypass (RYGB) surgery, obtained from PubMed searches (1990 to 2017) and reference searches of relevant retrieved articles. Whereas hypoglycemia can also be observed after sleeve gastrectomy and fundoplication, this review is focused on post-RYGB, given the greater body of published clinical studies at present. Outcome Measures: Data addressing specific aspects of diagnosis, pathophysiology, and treatment were reviewed by the authors; when not available, the authors have provided opinions based on clinical experience with this challenging condition. Conclusions: Hypoglycemia, occurring after gastric bypass surgery, is challenging for patients and physicians alike. This review provides a systematic approach to diagnosis and treatment based on the underlying pathophysiology.
AB - Context: Hypoglycemia, occurring after bariatric and other forms of upper gastrointestinal surgery, is increasingly encountered by clinical endocrinologists. The true frequency of this condition remains uncertain, due, in part, to differences in the diagnostic criteria and in the affected populations, as well as relative lack of patient and physician awareness and understanding of this condition. Postbariatric hypoglycemia can be severe and disabling for some patients, with neuroglycopenia (altered cognition, seizures, and loss of consciousness) leading to falls, motor vehicle accidents, and job and income loss. Moreover, repeated episodes of hypoglycemia can result in hypoglycemia unawareness, further impairing safety and requiring the assistance of others to treat hypoglycemia. Objective: In this review, we summarize and integrate data from studies of patients affected by hypoglycemia after Roux-en-Y gastric bypass (RYGB) surgery, obtained from PubMed searches (1990 to 2017) and reference searches of relevant retrieved articles. Whereas hypoglycemia can also be observed after sleeve gastrectomy and fundoplication, this review is focused on post-RYGB, given the greater body of published clinical studies at present. Outcome Measures: Data addressing specific aspects of diagnosis, pathophysiology, and treatment were reviewed by the authors; when not available, the authors have provided opinions based on clinical experience with this challenging condition. Conclusions: Hypoglycemia, occurring after gastric bypass surgery, is challenging for patients and physicians alike. This review provides a systematic approach to diagnosis and treatment based on the underlying pathophysiology.
UR - http://www.scopus.com/inward/record.url?scp=85049344404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049344404&partnerID=8YFLogxK
U2 - 10.1210/jc.2018-00528
DO - 10.1210/jc.2018-00528
M3 - Review article
C2 - 30101281
AN - SCOPUS:85049344404
SN - 0021-972X
VL - 103
SP - 2815
EP - 2826
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 8
ER -